J. Goldman & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

J. Goldman & Co’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-164,278	Closed	-$3.89M	–	444
2025 Q2	$3.54M	Buy	+164,278	New	+$3.05M	0.08%	232
2021 Q2	–	Sell	-8,647	Closed	-$223K	–	392
2021 Q1	$223K	Buy	+8,647	New	+$381K	0.01%	395
2019 Q2	–	Sell	-15,644	Closed	-$420K	–	259
2019 Q1	$420K	Buy	+15,644	New	+$365K	0.02%	239
2018 Q3	–	Sell	-123,769	Closed	-$1.89M	–	253
2018 Q2	$1.89M	Buy	+123,769	New	+$2.21M	0.1%	210

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

J. Goldman & Co's ACAD Position: Q3 2025 in Review

J. Goldman & Co sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 164,278 shares — an estimated $3.89M sold.

J. Goldman & Co first reported a position in ACAD in Q2 2018 and held it in 4 quarters. The position peaked at $3.54M in Q2 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

J. Goldman & Co reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
J. Goldman & Co sold 164,278 Acadia Pharmaceuticals shares in Q3 2025, an estimated $3.89M.
J. Goldman & Co first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 4 quarters.
J. Goldman & Co's Acadia Pharmaceuticals position peaked at $3.54M in Q2 2025.
334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.